Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07113210 · ClinicalTrials.gov registry record · Phase 4
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
A Phase 4 study of Dry Eye and Presbyopia, sponsored by Southern College of Optometry.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 2
- Study locations
NCT07113210: Recruiting Phase 4 study of Dry Eye and Presbyopia, sponsored by Southern College of Optometry.
NCT07113210 is a Phase 4 study of Dry Eye and Presbyopia that is actively recruiting participants, run by Southern College of Optometry. The registered enrollment target is 36 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07113210, a Phase 4 study of Dry Eye and Presbyopia, is actively recruiting participants, sponsored by Southern College of Optometry.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments * Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi™ at week 4 compared to baseline (continuous variable). * Improvement in presbyopic symptoms as measured with the Visual Quality of Life with Time Survey (VisQualT) questionnaire when using Qlosi™ at week 4 compared to baseline.
Primary Outcome
• Improvement in presbyopic symptoms as measured with the Near Activity Visual Questionnaire-Presbyopia (NAVQ-P) when using Qlosi at week 4 compared to baseline (continuous variable). In which higher scores are better.
Conditions Studied
Interventions
- DRUG pilocarpine HCL ophthalmic solution
Study Locations (2)
Minnesota
- Complete Eye Care of Medina - Medina
Tennessee
- The Southern College of Optometry - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2025-07-18 |
| Est. Completion | 2025-11-15 |
| Phase | Phase 4 |
What NCT07113210 shows while recruiting
NCT07113210 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (62% lower).
The record links to 3 conditions, with Dry Eye appearing as the primary indexed condition, and to 1 intervention - of which pilocarpine HCL ophthalmic solution is the first listed.
NCT07113210 reports a single indexed study location in Minnesota, Tennessee.
Frequently Asked Questions
What is clinical trial NCT07113210 about?
NCT07113210 is a clinical study titled "Quality of Life in Presbyopic Patients Who Are Treated With Qlosi". The goal of this clinical trial is to determine how Qlosi™ (pilocarpine HCL ophthalmic solution) 0.4%impacts the quality of life of participants with presbyopia by using a battery of validated and investigator-developed instruments * Improvement in presbyopic symptoms as measured with the Near Acti...
What is the current status of trial NCT07113210?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2025-07-18. Estimated completion is 2025-11-15.
What conditions does trial NCT07113210 study?
This clinical trial studies the following conditions: Dry Eye, Presbyopia, Glasses.
What interventions are being tested in trial NCT07113210?
The interventions under investigation include: pilocarpine HCL ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT07113210?
This trial is sponsored by Southern College of Optometry, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07113210 being conducted?
This trial has 2 study locations across Minnesota, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07113210's enrollment target sits among peer trials
36 27th of 41 higher than 14 of 41 other Dry Eye trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Dry Eye trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Kera Sol Tears on Signs and Symptoms of Surgical Temporary Ocular Discomfort Syndrome (STODS) in Subjects Following LASIK
RECRUITING · Phase 4
-
Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work
RECRUITING · Phase 4
-
Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune Disease
RECRUITING · Phase 4
-
Performance of Systane PRO Versus Refresh Optive Mega-3
RECRUITING · Phase 4
-
A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
ACTIVE NOT RECRUITING · Phase 4
-
DOMPE -MT Neurotrophic Keratitis
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI